A detailed history of Allspring Global Investments Holdings, LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 508 shares of SRPT stock, worth $53,106. This represents 0.0% of its overall portfolio holdings.

Number of Shares
508
Previous 21,777 97.67%
Holding current value
$53,106
Previous $3.44 Million 98.17%
% of portfolio
0.0%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$124.33 - $156.75 $2.64 Million - $3.33 Million
-21,269 Reduced 97.67%
508 $63,000
Q2 2024

Jul 26, 2024

SELL
$113.33 - $163.85 $27.1 Million - $39.2 Million
-239,511 Reduced 91.67%
21,777 $3.44 Million
Q1 2024

Apr 18, 2024

SELL
$93.7 - $141.53 $1.16 Million - $1.75 Million
-12,373 Reduced 4.52%
261,288 $33.8 Million
Q4 2023

Jan 25, 2024

SELL
$67.31 - $124.76 $5.44 Million - $10.1 Million
-80,841 Reduced 22.8%
273,661 $26.4 Million
Q3 2023

Oct 27, 2023

BUY
$102.5 - $123.59 $36.3 Million - $43.8 Million
354,502 New
354,502 $43 Million
Q2 2023

Jul 18, 2023

BUY
$106.4 - $157.19 $476,140 - $703,425
4,475 Added 0.83%
542,912 $62.2 Million
Q1 2023

Apr 13, 2023

BUY
$117.53 - $155.99 $18.9 Million - $25.1 Million
161,184 Added 42.73%
538,437 $74.2 Million
Q4 2022

Jan 23, 2023

BUY
$100.86 - $132.13 $11.4 Million - $14.9 Million
112,579 Added 42.53%
377,253 $48.9 Billion
Q3 2022

Oct 26, 2022

BUY
$75.71 - $119.24 $4.19 Million - $6.59 Million
55,306 Added 26.42%
264,674 $29.3 Million
Q2 2022

Jul 25, 2022

SELL
$62.69 - $88.44 $294,893 - $416,021
-4,704 Reduced 2.2%
209,368 $15.7 Million
Q1 2022

May 02, 2022

BUY
$63.15 - $90.42 $13.5 Million - $19.4 Million
214,072 New
214,072 $16.7 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.15B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.